Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GV101 in Friedreich's Ataxia
NCT07870590Phase 2Not yet recruiting
- Sponsor
- Graviton Biosciences
- Start
- Nov 2026
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of TDI01 in Friedreich's ataxia (FA) (4 arms), sponsored by Graviton Biosciences. Primary endpoint: Frataxin-M protein at 12 weeks. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
TDI01
03
Conditions
Friedreich's ataxia (FA)
Beyond the preview
Go deeper on NCT07870590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07870590.